CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that the company will participate in two upcoming investor conferences:
On Friday, March 23, at 3:00 p.m. ET, Paula Ragan, PhD, President and Chief Executive Officer, will present a company overview at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York, NY. A breakout session will follow the presentation at 3:30 p.m.
On Wednesday, March 28, at 11:00 a.m ET, Dr. Ragan will make a presentation on X4 at Needham & Company’s 17thAnnual Healthcare Conference at the Westin Grand Central in New York, NY.
About X4 Pharmaceuticals
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. The Company’s oral small molecule drug candidates inhibit the CXCR4 receptor, a pathway which plays a central role in immune surveillance. X4’s most advanced product candidate, X4P-001-RD, is in a Phase 2/3 study in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease. X4P-001-IO is currently under investigation in multiple Phase 1/2 studies in refractory clear cell renal cell carcinoma (ccRCC) and melanoma. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA. For more information please visit X4pharma.com.